Protecting the Healthcare Supply Chain
The Indian government has announced a customs duty exemption on 40 petrochemical inputs to support the pharmaceutical and medical technology sectors. Consequently, this move aims to mitigate the heavy cost burden stemming from the ongoing West Asia conflict. The Finance Ministry confirmed that this relief will last until June 30, 2026, to stabilize domestic manufacturing costs. For many manufacturers, raw material prices have surged by 50 percent since the conflict began. Therefore, the industry appreciates these proactive measures to prevent supply-related disruptions for essential medicines.
Impact of the Customs Duty Exemption
Specifically, materials like Polypropylene and PVC resin form the core of medical consumables manufacturing. Without this relief, the skyrocketing prices of petrochemical feedstocks would have crippled local production units. Moreover, shortages of helium gas have already hampered the assembly of critical diagnostic tools like MRI scanners. By waiving these duties, the government helps maintain the affordability of syringes, catheters, and IV sets for patients. Furthermore, the Association of Indian Medical Device Industry (AiMeD) had earlier requested these refunds to offset higher freight charges caused by shipping blockades.
Addressing the Inverted GST Structure
While the duty waiver provides short-term relief, manufacturers still face long-term financial challenges. Notably, industry leaders are urging the government to lower the GST on raw materials from 18 to 5 percent. Because the current tax structure remains inverted, domestic producers struggle to compete with imported finished goods. Additionally, the Indian Pharmaceutical Alliance (IPA) has called for an “Empowered Committee of Secretaries” for better coordination. Such a committee would monitor stakeholders continuously to ensure the uninterrupted supply of critical life-saving goods in the future.
Frequently Asked Questions
Q1: How will the customs duty exemption help the medical sector?
The exemption reduces the input costs for 40 petrochemical materials. This allows manufacturers to keep essential products like syringes and IV bags affordable despite global supply chain disruptions.
Q2: Which materials are included in the duty waiver?
The list includes critical polymers and resins such as Polypropylene, ABS, Polycarbonate, and PVC resin. These materials are vital for making medical consumables and housing for diagnostic equipment.
Q3: Why is the pharmaceutical industry demanding GST rationalization?
The industry faces an inverted duty structure where inputs attract 18 percent GST while finished goods are taxed lower. Reducing the input GST to 5 percent would improve the global competitiveness of “Made in India” medical products.
References
- Centre gives custom cushion to supply strained Pharma, MedTech manufacturers – ETHealthworld
- Fortune India: Custom duty exemption on critical petrochemical products to benefit auto, pharma, textiles, plastics sector.
- Medgate Today: India’s Medical Device Industry Seeks Duty Relief as West Asia Conflict Drives Up Input Costs.
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.